Minnesota Rubber and Plastics Acquires Primasil Silicones Ltd.

Primasil offers a wide range of custom materials, including platinum-cured silicone, conductive silicone, flourosilicone, high- and low-temperature silicone, low smoke and toxicity silicone and black rubber.

Quadion LLC, d.b.a. Minnesota Rubber and Plastics (MRP), a leading provider of highly engineered elastomer and thermoplastic solutions for the medical, water and specialty industrial end markets, announced today its acquisition of Primasil Silicones Ltd. (Primasil), a Weobley, U.K.-based custom silicone rubber compounder, mixer and manufacturer specializing in the medical, HVAC and specialty industrial end markets.

“We’re thrilled to add Primasil, a company with four decades of silicone materials science expertise, to our family. Primasil’s custom material formulation, mixing and molding expertise will complement Minnesota Rubber and Plastic’s renowned materials science and molding capabilities. It will also provide a wide variety of new solutions for our clients,” said Jay Ward, CEO of Minnesota Rubber and Plastics.

Ward noted, “We have a long history of successfully serving our customers in Europe, and the addition of a highly technical production presence in the U.K. and Czech Republic will allow us to take our local capabilities to the next level. Not only will the acquisition augment our materials science and manufacturing capabilities, but it will also expand our global scope – particularly in the medical end market – and further our plans to expand our European footprint while we actively look to partner and acquire technical elastomer companies across the region.”

Primasil offers a wide range of custom materials, including platinum-cured silicone, conductive silicone, flourosilicone, high- and low-temperature silicone, low smoke and toxicity silicone and black rubber. Primasil’s proprietary silicone expertise will contribute to MRP’s materials science-driven Innovation Center, launching Spring 2022.

Furthermore, Primasil’s high precision manufacturing capabilities include cleanroom molding, extrusion and assembly as well as mixing, injection molded and proprietary gum silicone and liquid silicone rubber (LSR) products.

The addition of Primasil’s capabilities will complement MRP’s existing offerings, which include highly engineered elastomer and thermoplastic solutions for the medical device, water, food and beverage, infrastructure and other essential industries globally. MRP built its strong reputation over its more than 75-year history for designing, developing, manufacturing and assembling products for harsh environments, tight tolerances and technically demanding applications, including multi-material solutions and custom material formulations.

“The Primasil team is extremely excited about this opportunity. We look forward to working alongside our new colleagues at Minnesota Rubber and Plastics to continue serving our valued customers – in Europe and around the globe – with innovative technologies, great talent and more options than ever before,” said Steve Wheeler, Managing Director of Primasil. “We’re not just acquiring great products and capabilities to complement our current offerings; we’re adding a world-class team. We plan to extend ownership to all of the new colleagues we welcome onboard from Primasil,” added Ward.

Wheeler will continue to lead Primasil, reporting into the MRP organization. For more information about Minnesota Rubber and Plastics and its current offerings.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.